Fetal valproate syndrome: A review

Paediatric and Perinatal Drug Therapy

Volumn 7, Issue 3, 2006, Pages 123-130

  Kini, Usha ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Behavioural problems; Learning difficulties; Malformations; Pregnancy; Teratogenicity; Valproate

Indexed keywords

CARBAMAZEPINE; PHENOBARBITAL; VALPROIC ACID;

ABDOMINAL WALL DEFECT; AGYRIA; ANENCEPHALUS; ANTICONVULSANT ACTIVITY; AORTA STENOSIS; BEHAVIOR DISORDER; BIPOLAR DISORDER; BIRTH DEFECT; BONE DEFECT; BRAIN ARACHNOID CYST; BRAIN ATROPHY; BRAIN MALFORMATION; CAMPTODACTYLY; CAPILLARY HEMANGIOMA; CLINICAL FEATURE; CONGENITAL CATARACT; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CONGENITAL SKIN DISEASE; CORNEA OPACITY; CORPUS CALLOSUM AGENESIS; DANDY WALKER SYNDROME; DEVELOPMENTAL DISORDER; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; EPILEPSY; EYE MALFORMATION; FACE DYSMORPHIA; FETAL VALPROATE SYNDROME; FETUS DISEASE; HAND MALFORMATION; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYDRANENCEPHALY; HYDRONEPHROSIS; HYPOPLASIA; HYPOSPADIAS; IRIS DISEASE; JOINT LAXITY; KIDNEY HYPOPLASIA; LACRIMATION DISORDER; LARYNX DISORDER; LEARNING DISORDER; LIMB DEFECT; LUNG DISEASE; LUNG HYPOPLASIA; MICROCEPHALY; MICROPHTHALMIA; MIDDLE EAR EFFUSION; MYOPIA; NEURAL TUBE DEFECT; OPTIC NERVE HYPOPLASIA; OTITIS MEDIA; PATENT DUCTUS ARTERIOSUS; POLYDACTYLY; PORENCEPHALY; PRACTICE GUIDELINE; PREGNANCY; PRENATAL DRUG EXPOSURE; PULMONARY ARTERY MALFORMATION; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SKIN APLASIA; SPINA BIFIDA; STRABISMUS; TEAR DUCT ANOMALY; TERATOGENESIS; TERATOGENICITY; TOE MALFORMATION; TRACHEOMALACIA; URETHRA DUPLICATION; UROGENITAL TRACT DISEASE;

EID: 33845735209     PISSN: 14630095     EISSN: None     Source Type: Journal    
DOI: 10.1185/146300906X112908     Document Type: Review

References (61)

1. Lindhout D, Omtzigt JG. Pregnancy and the risk of teratogenicity. Epilepsia 1992;33:S41-S48
2. Gurvich N, Berman MG, Wittner BS et al. Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J 2005;19:1166-1168. Epub 2005 May 18
3. Clayton-Smith J, Donnai D. Fetal valproate syndrome. J Med Genet 1995;32:724-727
4. Bailey DN, Briggs JR. Valproic acid binding to human serum and human placenta in vitro. Ther Drug Monit 2005;27:375-377
5. Dalens B, Raynaud EJ, Gaulme J. Teratogenicity of valproic acid. J Pediatr 1980;97:332-333
6. DiLiberti JH, Farndon PA, Dennis NR, Curry CJ. The fetal valproate syndrome. Am J Med Genet 1984;19:473-481
7. Ardinger HH, Atkin JF, Blackston RD et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988;29:171-185
8. Dean JC, Hailey H, Moore SJ, Lloyd DJ, Turnpenny PD. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 2002;39:251-259
9. Williams G, King J, Cunningham M et al. Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol 2001;43:202-206
10. Kallen B. Epidemiology of human reproduction. London: CRC Press, 1988:133-139
11. Adab N, Tudur SC, Vinten J, Williamson P, Winterbottom J. Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database Syst Rev 2004;3:CD004848
12. Yerby MS. Pregnancy, teratogenesis, and epilepsy. Neurol Clin 1994;12:749-771
13. Nelson KB, Ellenberg JH. Maternal seizure disorder, outcome of pregnancy, and neurologic abnormalities in the children. Neurology 1982;32:1247-1254
14. Kozma C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet 2001;98:168-175
15. Kini U, Adab N, Vinten J, Fryer A, Clayton-Smith J; Liverpool and Manchester Neurodevelopmental Study Group. Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes. Arch Dis Child Fetal Neonatal Ed 2006;91:F90-F95. Epub 2005 Oct 20
16. Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989;320:1661-1666
17. Ebbesen F, Joergensen A, Hoseth E et al. Neonatal hypoglycaemia and withdrawal symptoms after exposure in utero to valproate. Arch Dis Child Fetal Neonatal Ed 2000;83:F124-F129
18. Holmes LB, Harvey EA, Coull BA et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344:1132-1138
19. Kaneko S, Battino D, Andermann E et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-158
20. Samren EB, van Dujin CM, Koch S. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38:981-990
21. Morrow J, Russell A, Guthrie E et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-198. Epub 2005 Sep 12
22. Wyszynski DF, Nambisan M, Surve T et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-965
23. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982;2:937
24. Robert E, Rosa F. Valproate and birth defects. Lancet 1983;ii:1142.
25. Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1986;1:1392-1393
26. Nau H, Scott WJ. Teratogenicity of valproic acid and related substances in the mouse: drug accumulation and pH in the embryo during organogenesis and structure-activity considerations. Arch Toxicol Suppl 1987;11:128-139
27. Omtzigt JG, Los FJ, Grobbee DE et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992;42:119-125
28. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-677
29. Martinez-Frias ML. Clinical manifestation of prenatal exposure to valproic acid using case reports and epidemiologic information. Am J Med Genet 1990;37:277-282
30. Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992;42:111-118
31. Mo CN, Ladusans EJ. Anomalous right pulmonary artery origins in association with the fetal valproate syndrome. J Med Genet 1999;36:83-84
32. Rodriguez-Pinilla E, Arroyo I, Fondevilla J, Garcia MJ, Martinez-Frias ML. Prenatal exposure to valproic acid during pregnancy and limb deficiencies: a case-control study. Am J Med Genet 2000;90:376-381
33. Verloes A, Frikiche A, Gremillet C et al. Proximal phocomelia and radial ray aplasia in fetal valproic syndrome. Eur J Pediatr 1990;149:266-267
34. Sharony R, Garber A, Viskochil D et al. Preaxial ray reduction defects as part of valproic acid embryofetopathy. Prenat Diagn 1993;13:909-918
35. Espinasse M, Manouvrier S, Boute O, Farriaux JP. Embryofetopathy due to valproate: a pathology only little known. Apropos of 4 cases. Arch Pediatr 1996;3:896-899
36. Sukumaran S, Krishnamoorthy T, Thomas SV. Split-hand/split-foot malformation associated with maternal valproate consumption. Neurol India 2005;53:251-252
37. Pandya NA, Jani BR. Post-axial limb defects with maternal sodium valproate exposure. Clin Dysmorphol 2000;9:143-144.
38. Buntinx IM. Preaxial polydactyly in the fetal valproate syndrome. Eur J Pediatr 1992;151: 919-920.
39. Jager-Roman E, Deichl A, Jakob S. Fetal growth, major malformations and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986;108:997-1004
40. Bailey CJ, Pool RW, Poskitt EM, Harris F. Valproic acid and fetal abnormality. Br Med J 1983;286:190
41. Huot C, Gauthier M, Lebel M, Larbrisseau A. Congenital malformations associated with maternal use of valproic acid. Can J Neurol Sci 1987;14: 290-293
42. Bantz EW. Valproic acid and congenital malformations. A case report. Clin Pediatr (Phila) 1984;23:352-353
43. Lajeunie E, Barcik U, Thorne JA et al. Craniosynostosis and fetal exposure to sodium valproate. J Neurosurg 2001;95:778-782
44. Winter RM, Donnai D, Burn J, Tucker SM. Fetal valproate syndrome: is there a recognisable phenotype? J Med Genet 1987;24:692-695
45. Mawer G, Clayton-Smith J, Coyle H, Kini U. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure 2002;11:512-518
46. Moore SJ, Turnpenny P, Quinn A, Glover S et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000;37:489-497
47. Adab N, Kini U, Vinten J et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-1583
48. Miyazaki K, Narita N, Narita M. Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism. Int J Dev Neurosci 2005;23:287-297
49. Friedman JM, Polifka JE. Teratogenic effects of drugs. A Resource for Clinicians (TERIS) Baltimore, John Hopkins University Press, 1994:639-643
50. Kerr BM, Levy RH. Inhibition of epoxide hydrolase by anticonvulsants and risk of teratogenicity. Lancet 1989;1:610-611
51. Scott WJ Jr, Schreiner CM, Nau H et al. Valproate-induced limb malformations in mice associated with reduction of intracellular pH. Reprod Toxicol 1997;11:483-493
52. Liu L, Wells PG. In vivo phenytoin-initiated oxidative damage to proteins and lipids in murine maternal hepatic and embryonic tissue organelles: potential molecular targets of chemical teratogenesis. Toxicol Appl Pharmacol 1994;125:247-255
53. Keen CL, Peters JM, Hurley LS. The effect of valproic acid on 65Zn distribution in the pregnant rat. J Nutr 1989;119:607-611
54. Hurd RW, Wilder BJ, Van Rinsvelt HA. Valproate, birth defects and zinc. Lancet 1983;1:181
55. Faiella A, Wernig M, Consalez GG et al. A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression. Hum Mol Genet 2000;9:227-236
56. Dean JC, Moore SJ, Osborne A, Howe J, Turnpenny PD. Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. Clin Genet 1999;56:216-220
57. Finnell RH, Wlodarczyk BC, Craig JC, Piedrahita JA, Bennett GD. Strain-dependent alterations in the expression of folate pathway genes following teratogenic exposure to valproic acid in a mouse model. Am J Med Genet 1997;70:303-311
58. Kawanishi CY, Hartig P, Bobseine KL et al. Axial skeletal and Hox expression domain alterations induced by retinoic acid, valproic acid, and bromoxynil during murine development. J Biochem Mol Toxicol 2003;17:346-356
59. Omtzigt JGC. Epilepsy, antiepileptic drugs and birth defects. Erasmus University, Rotterdam, The Netherlands, 1992
60. Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004;75:75-79
61. Crawford P, Appleton R, Betts T et al. Best practice guidelines for the management of women with epilepsy. The Women with Epilepsy Guidelines Development Group. Seizure 1999;8:201-217